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Characteristics of infants hospitalized 
with bronchiolitis at University Hospital 
of Split between 2011 and 2015
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The aim was to determine and analyze clinical and epidemiological characteristics of infants treated at University Hospital of Split 
from 2011 to 2015 with the diagnosis of bronchiolitis. Bronchiolitis is an acute lower respiratory tract infection common in early 
childhood. The most frequent etiologic agent is respiratory syncytial virus (RSV) found in 60% to 80% of cases. Coughing, wheezing 
and impaired nutrition are the major symptoms. Medical records of children under the age of one year who were hospi talized at 
University Hospital of Split due to bronchiolitis between January 1, 2011 and December 31, 2015 were retrospectively  analyzed. A 
total of 560 infants were hospitalized during the 5-year period, out of them 340 were males. The most frequent symptoms were nasal 
congestion, followed by wheezing, fever >38 °C, and crackles. Rapid antigen test for RSV was conducted in 193 infants and was 
positive in 134 (69.4%) cases. Bronchodilators were administered in a vast majority of infants (74.5%), whereas inhaled corticoste-
roids were used in 24.6% and racemic adrenaline in 14.1% of infants. Additional oxygen therapy was required only in 5% of cases. 
Study results confi rmed the greater incidence of bronchiolitis in boys and the mean duration of hospital stay was 7.6±3.3 days. Anti-
biotic therapy was administered in 85.2% of infants, which is considerably higher than in other published studies. Therefore, 
 additional eff ort should be invested to lower antibiotic administration.
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INTRODUCTION
Bronchiolitis is an acute lower respiratory tract infection 
usually presenting in early childhood with coughing, wheez-
ing, and feeding problems (1). Approximately 20% of chil-
dren develop acute bronchiolitis in the fi rst year of life and 
2%-3% of them, most frequently infants between 30 and 60 
days of age, will be hospitalized (2, 3). Bronchiolitis is gener-
ally seasonal, appearing most frequently in epidemics dur-
ing the winter months. Respiratory syncytial virus (RSV) 
causes 60%-80% of cases (4). For RSV, the same seasonal 
pattern is observed throughout the northern hemisphere, 
with most cases occurring from October until May. Adults 
with chronic obstructive pulmonary disease and other 
 immunocompromised patients may have RSV infection 
throughout the year and represent a reservoir of the virus 
(5). Diagnosis of bronchiolitis is based on the combination 
of clinical characteristics, infant age, period of the year, and 
physical examination. Bronchiolitis usually starts with rhi-
norrhea and fever, and within few days spreads to lower 
airways resulting in symptoms of obstructive dyspnea (6). 
Depending on the severity of the disease, cyanosis can be 
present, whereas in most severe cases apnea can occur (2, 7, 
8). Infl ammation in the bronchioles is characterized by peri-
bronchial infi ltration of white blood cells, mostly mononu-
clear cells, as well as edema of the submucosa and adventi-
tia (9). Edema, mucus secretion, and damage to the airway 
epithelium with necrosis may cause partial or total airfl ow 
obstruction, distal air trapping, atelectasis, and ventilation 
perfusion mismatch leading to hypoxemia (9). As the dis-
ease progresses, drowsiness and lethargy may occur, and 
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shortness of breath, dyspnea, nasal secretion and feeding 
problems will be more pronounced (10). In 2006, the Scot-
tish Intercollegiate Guidelines Network (SIGN) issued a clini-
cal scoring system classifying bronchiolitis into mild, mod-
erate and severe forms (11). Chest radiography is not usually 
recommended as a routine test, but it can be useful in chil-
dren with severe bronchiolitis (12). Etiologic diagnosis is 
most often made by using rapid viral antigen test. This test 
has a high predictive value and meets the criteria of both 
price and speed (13, 14).
A conservative approach to treatment seems appropriate in 
the majority of children, especially the youngest ones. The 
treatment is generally supportive, as no other treatment has 
been shown to improve important clinical outcomes (1, 3). In 
2006, guidelines were issued in New Zealand to help doctors 
decide whether or not there is a need of hospitalization (9).
The aim of this research was to determine and analyze clini-
cal and epidemiological characteristics of infants treated at 
University Hospital of Split between 2011 and 2015 with the 
diagnosis of bronchiolitis.
MATERIAL AND METHODS
We conducted a retrospective analysis of all children young-
er than one year, diagnosed with bronchiolitis and hospital-
ized for more than 24 hours at University Hospital of Split 
between January 1, 2011 and December 31, 2015. The diag-
nosis was made clinically, as described elsewhere (3). The 
infants were hospitalized if bronchiolitis was classifi ed as 
moderate or severe (11). Patient data were obtained from 
medical records. Children with hemodynamically signifi -
cant heart disease, chromosomal anomalies, immunodefi -
ciency (e.g., Di George syndrome), cystic fi brosis, broncho-
pulmonary dysplasia and epileptic encephalopathy were 
not included in the study. The Ethics Committee of the Uni-
versity Hospital of Split approved the study and the parents 
or guardians of the included infants signed the informed 
consent. Data analysis was performed using the Microsoft 
Excel 2010 software (Microsoft, Redmond, USA).
RESULTS
During the study period, 560 infants were admitted to De-
partment of Pediatrics, University Hospital of Split with 
bronchiolitis. There were 340 (60.7%) male and 220 (39.3%) 
female infants. Demographic characteristics are shown in 
Table 1. Regarding the method of delivery, 433 (77.7%) in-
fants were born via vaginal delivery and 124 (22.3%) infants 
via cesarean delivery. For three infants, the method of deliv-
ery was not noted in medical charts.
At the time of admission, oxygen saturation was assessed 
by pulse oximetry in 342 (61.1%) infants (mean ± standard 
deviation (SD), 95±4.3%). All values were obtained at room 
air, without administration of supplemental oxygen. Other 
clinical symptoms/signs are shown in Table 2.
Respiratory syncytial virus testing was ordered in all conse-
quently admitted infants regardless of symptom severity, 
and was performed when available. Rapid RSV antigen test-
ing was done in 193 (34.5%) infants and was positive in 134 
(69.4%) infants. The mean duration of hospitalization was 
7.6±3.3 days. The majority of infants were treated with anti-
biotic therapy (n=477, 85.2%) and inhalational bronchodila-
tors (n=417, 74.5%), followed by inhaled corticosteroids 
(n=138, 24.6%) and with racemic epinephrine (n=79, 14.1%). 
Ceftriaxone was the most frequently administered antibi-
otic (n=223, 46.7%), followed by a combination of ceftriax-
one and azithromycin (n=148, 31%) and azithromycin alone 
(n=68, 14.3%). Additional oxygen via facemask or nasal 
prongs was administered in 28 (5%) infants. 
TABLE 2. Clinical symptoms/signs found in infants hospitalized 
for bronchiolitis (N=560)
Symptom / sign Number (percentage)
Copious nasal secretion 383 (68.4%)
Wheezing 184 (32.9%)
Fever >38° 168 (30%)
Crackles 144 (25.7%)
Cyanosis 16 (2.9%)
Episodes of apnea 2 (0.4%)
TABLE 1. Demographic characteristics of infants hospitalized for bronchiolitis
Characteristic / number of patients Mean ± Standard deviation Males Females
Age at admission (N=560) (months) 4.7 ± 3.27 4.84 ± 3.25 4.47 ± 3.3
Body weight at admission (N=560) (g) 6536,72 ± 2040,49 6830,15±2130,87 6083,23±1085,19
Body length at admission (N=503) (cm) 63,93 ± 7,85 65,07±8,05 62,16±4,31
Birth weight (N=557) (g) 3326,88 ± 772,36 3414,01±735,53 3191,37±809,63
Birth length (N=556) (cm) 49,36 ± 3,82 50,12±3,51 49,00±4,19
Gestational age (N=557) (weeks) 38,61 ± 3,05 38,62±2,87 38,58±3,33
55
PAEDIATR CROAT. 2017;61:53-8 MILIĆ P., SIKIRICA M. KRŽELJ V., MARKIĆ J. INFANTS WITH BRONCHIOLITIS AT UNIVERSITY HOSPITAL OF SPLIT.
DISCUSSION
In this research, clinical and epidemiological characteristics 
of infants hospitalized for bronchiolitis at University Hospital 
of Split are presented. The majority of our patients were 
males (60.7%). Although there are other studies reporting 
that boys are generally more likely to be diagnosed with 
bronchiolitis and diff erent mechanisms have been pro-
posed to explain this issue, it is still not fully understood. The 
mean age of the hospitalized infants was 4.7 months. This is 
higher than in four major hospitals in the northeastern Unit-
ed States of America, where the average age at admission 
was 68 (67-88) days (15). However, similar results were found 
in a European study conducted in University Hospital of 
 Geneva where the mean age was 4.57±3.4 (range 0.3-11.8) 
months (16). Due to fi nancial restrictions, in our study, rapid 
RSV antigen testing was done when available in 193 (34.5%) 
infants and was positive in 134 (69.4%) infants tested. Better 
understanding of bronchiolitis etiology and the emergence 
of more advanced techniques for viral detection have raised 
the question of the relevance of the etiologic agent in the 
course of the disease. As concluded in the previously men-
tioned study, RSV-positive patients have a heavier econom-
ic impact; and it was shown that these patients have gener-
ally longer duration of hospitalization, oxygen therapy and 
nasogastric tube requirements (16). However, diff erent from 
other studies, their study indicates that at the individual 
level, as a performance test, virology testing alone seems 
insuffi  cient to precisely predict the outcomes (16). There-
fore, virology testing should not be routinely done in all pa-
tients presenting to emergency department because it may 
increase costs without adding signifi cant further informa-
tion. These fi ndings warrant additional validation and analy-
sis in prospective studies.
Wheezing was the most frequent sign of bronchiolitis in our 
study, recorded in 32.6% of infants. In a study conducted in 
New York, the same symptom was found in 16% to 49% of 
participants. The authors observed no signifi cant correla-
tion between the presence of wheezing on physical exami-
nation and the severity of illness or level of saturation (17).
The main goal of bronchiolitis treatment is to regularly as-
sess the patient and to ensure that he/she is clinically stable, 
well oxygenated and well hydrated. Placing an infant in a 
drainage position to ease breathing and gentle nasal suc-
tion to keep the airway patent is benefi cial in infants with 
copious secretion and can lead to improvement in infants 
with a less severe form of bronchiolitis (1). Inhalation of hy-
pertonic saline has been shown to increase mucociliary 
clearance, possibly through induction of the osmotic fl ow 
of water to the mucus layer and by breaking ionic bonds 
within the mucus gel. A meta-analyses including infants 
with mild to moderate bronchiolitis concludes that the use 
of hypertonic saline (3%-5%) may reduce the length of hos-
pital stay and the rate of hospitalization (18). However, con-
fl icting results have been reported from a study where Re-
spiratory Distress Assessment Instrument scores showed no 
improvement after nebulization with hypertonic saline. It 
was also shown that hypertonic saline nebulization had no 
short-term eff ect on wheezing, breathing frequency, or in-
spiration/expiration ratios in children admitted for RSV 
bronchiolitis (19). Considering heterogeneity of the eff ect 
sizes and combined treatment modalities in all studies, the 
eff ect of monotherapy with nebulized hypertonic saline re-
mains unclear. Oxygen should be administered in hypoxic 
infants with bronchiolitis, and administered via nasal can-
nula or facemask (1). However, there is no consensus on the 
level of oxygen saturation (SpO
2
) we should be aiming at, 
and no randomized controlled trials have compared alter-
native oxygen supplementation regimens (1). In the United 
Kingdom, oxygen is commonly given to achieve SpO
2
 of 
92%-95% (1), whereas in accordance with the American 
Academy of Pediatrics (AAP) guidelines, supplemental oxy-
gen should be administered if SpO2 levels are persistently 
below 90% at ambient air (3, 20). It is important to measure 
SpO2 correctly by pulse oximetry using pediatric probes, 
with nasal aspiration prior to measurement, and when the 
child is not moving limbs or is hypothermic. In our study, it 
was necessary to administer oxygen therapy in 5% of the 
infants, similar to the research conducted in Connecticut in 
which 8% of the participants were placed on oxygen thera-
py (21). However, there are much higher reported values, as 
in the study where oxygen therapy was administered in 
22.5% to up to 36.8% of the infants with bronchiolitis (17). 
High fl ow oxygen therapy with humidifi ed and heated oxy-
gen (High Flow Nasal Cannula, HFNC) is a new noninvasive 
ventilation support modality that generates positive pres-
sure in the pharynx and decreases workload of respiratory 
muscles. Studies suggest that the use of HFNC may rapidly 
improve oxygen saturation in infants suff ering from bron-
chiolitis (22).
The most commonly used inhalation treatments are beta-
2-agonists and racemic adrenaline. In our study, 74.5% of 
infants were given inhalation of salbutamol as part of the 
management of bronchiolitis, similar to another research 
where 72% of patients were given bronchodilators (21). Two 
recent systematic reviews (23, 24) have confi rmed that in-
haled beta agonists are not eff ective for bronchiolitis, as 
they do not improve oxygen saturation, do not decrease 
the need for and length of hospital stay, nor reduce overall 
duration of symptoms. Inhalation with adrenaline should 
reduce mucosal swelling and it has led to its frequent use in 
infants with bronchiolitis. However, no clinically important 
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eff ect has been documented for either adrenaline or beta-
2-agonists (24, 25). Studies from two hospitals in New York 
showed the frequency of antibiotic therapy administration 
of 23.4% and 36.4% patients with bronchiolitis, respectively 
(17). Often, clinicians are concerned that, if they do not use 
antibiotics in an infant presenting with fever and clinical 
symptoms and signs of severe form of bronchiolitis, they 
may be putting a child at a risk of serious complications 
such as pneumonia, septicemia and death. There also are 
analyses suggesting a relationship between RSV and pneu-
mococcal pneumonia hospitalizations since RSV is associ-
ated with increases in the incidence of pneumococcal 
pneumonia, particularly in young infants (26). That was the 
reason why antibiotic therapy was administered in the vast 
majority of patients (85.2%) in this study. There are insuffi  -
cient data to support the use of antibiotics in bronchiolitis 
in children although they are used at rates of 34% to 99% in 
uncomplicated cases, but they can be justifi ed in the case 
of concomitant bacterial infections in infants with severe 
disease and respiratory failure (27). Macrolides are thought 
to have anti-inflammatory activities, as well as antibiotic ac-
tivity (28), and so were thought to have a potential in treat-
ing bronchiolitis caused by viruses. In our study, azithromy-
cin was administered in 14.3% of patients. However, a study 
examining azithromycin, a macrolide antibiotic, confi rmed 
the hypothesis that macrolide antibiotics would make no 
diff erence in bronchiolitis (29). Another two studies also 
demonstrated no statistically significant benefit of azithro-
mycin compared to placebo for their primary outcomes (30, 
31). The latest Cochrane review article indicates that admin-
istration of antibiotic therapy does not result in shortening 
of the length of hospitalization (32). We can conclude that 
the habitual use of antibiotics for bronchiolitis must be 
avoided because of the risk of side eff ects, signifi cant costs, 
and possible development of antibiotic resistance.
The data obtained in our study showed that corticosteroid 
therapy was used in the management of 24.6% of the par-
ticipants. The use of corticosteroids in bronchiolitis is con-
troversial. On the one hand, a combined use of oral cortico-
steroids and racemic epinephrine was shown to lead to 
shortening of hospital stay (33). Van Woensel et al. demon-
strated that dexamethasone (0.15 mg/kg every 6 hours for 
48 hours) could be useful in mechanically ventilated chil-
dren or critically ill children in general (34). On the other 
hand, the Pediatric Emergency Care Applied Research Net-
work multicenter study found that a single oral dose of 
dexamethasone was not much more eff ective than placebo 
during treatment of the fi rst episode of bronchiolitis in pre-
viously healthy children (35). Furthermore, a Cochrane me-
ta-analysis including 17 randomized controlled trials con-
cluded that there was no benefi cial eff ect of inhaled corti-
costeroids in children with bronchiolitis, either on the rate 
of hospitalization for outpatients or on the length of stay for 
inpatients (36).
In our population of infants with bronchiolitis, the frequen-
cy of treatments with antibiotics and bronchodilators was 
high. This prevalence suggests that these therapies contin-
ue to be used routinely, perhaps due to the perceived ben-
efi t. Nonetheless, the small number of treatments eff ective 
for bronchiolitis emphasizes the importance of prevention 
in decreasing the impact of this disease. It has been esti-
mated that up to 13% of childhood asthma cases could be 
prevented by primary prevention of RSV bronchiolitis (37). 
This concept is supported by two trials demonstrating re-
ductions in early life wheezing among late-preterm chil-
dren who received the anti-RSV monoclonal antibody 
palivizumab (38, 39). Palivizumab immunoprophylaxis con-
sists of a monoclonal antibody to glycoprotein F of RSV. It 
signifi cantly reduces the number of hospitalizations of in-
fants with risk factors such as bronchopulmonary dysplasia, 
prematurity, and hemodynamically signifi cant congenital 
heart disease. Therefore, in our hospital, infants born at a 
gestational age ≤32 weeks and younger than six months at 
the beginning of the RSV epidemic season receive palivi-
zumab once a month for fi ve months during the season. 
Although palivizumab is an eff ective modality for the pre-
vention of RSV infection and subsequent wheezing, its use 
has limitations: it is expensive, requires monthly injections 
during the RSV season, has not been studied in full term in-
fants, and is unlikely to be feasible for routine use in large 
populations. There is a need to identify other pharmaco-
logical interventions that could be used in children hospi-
talized for RSV bronchiolitis, which may prevent subsequent 
recurrent wheezing. Zhivaki et al. found a neonatal-specific 
regulatory B cell that is recruited in the respiratory tract, 
gets infected by the virus, and correlates with high viral load 
and disease severity (40). nBreg cells represent a newly de-
scribed target cell for RSV and a biomarker for the severity of 
acute bronchiolitis. Their activity may constitute an early-life 
host response that favors microbial pathogenesis and may 
represent a target for the treatment of low respiratory tract 
viral infections and their pathologic consequences later in 
life (40).
The length of hospital stay in this study was 7.6±3.3 days. 
These data can be compared with those obtained in a sur-
vey conducted in Norway, where the average length of hos-
pital stay was 80±67 hours (41). In another research, the 
length of hospitalization of infants in the intensive care was 
5.3±8.5 days, while the length of hospitalization on the 
ward was 2.9±1.6 days (15). Although our hospitalization 
time was longer, it is comparable with the results from a 
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study where the mean length of hospital stay was 5.7±8.2 
days (42).
There were limitations in this study. Due to the retrospective 
nature of our study, we were limited to the data that were 
available in medical records for clinical purposes only. Also, 
viral and bacterial tests were not performed in all children of 
this cohort.
In conclusion, the recent clinical practice guidelines do not 
recommend administration of albuterol (or salbutamol) and 
nebulized epinephrine to infants and children diagnosed 
with bronchiolitis. However, our study revealed that the fre-
quency of bronchodilators, corticosteroids and racemic epi-
nephrine administration was high in our institution, per-
haps due to the perceived benefi t. Also, antibiotics were 
administered in 85.2% of the subjects. Therefore, it is advis-
able to adjust our practice to the existing guidelines and 
additional eff ort should be invested to lower antibiotic ad-
ministration. Antibiotics should be administered when 
there is a concomitant bacterial infection, or if it is strongly 
suspected.
Abbreviations:
RSV - respiratory syncytial virus
AAP - American Academy of Pediatrics
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S A Ž E T A K
Značajke dojenčadi hospitalizirane zbog bronhiolitisa 
u KBC Split od 2011. do 2015. godine
Petra Milić, Maja Sikirica, Vjekoslav Krželj, Joško Markić
Cilj istraživanja bio je utvrditi i analizirati kliničke i epidemiološke značajke dojenčadi s dijagnozom bronhiolitisa i liječene u Klinič-
kom bolničkom centru Split od 2011. do 2015. godine. Bronhiolitis je akutna infekcija donjega dišnog sustava koja je česta u ranom 
djetinjstvu. Najčešći etiološki uzročnik je respiracijski sincicijski virus (RSV) koji se nalazi u 60% do 80% slučajeva. Glavni simptomi su 
kašalj, sipnja i poteškoće pri hranjenju. Retrospektivno su analizirani medicinski zapisi djece mlađe od jedne godine hospitalizirane u 
KBC Split zbog bronhiolitisa od 1. siječnja 2011. do 31. prosinca 2015. godine. Tijekom 5-godišnjeg razdoblja hospitalizirano je 
 ukupno 560 dojenčadi, 340 od njih muškog spola. Najčešći simptomi bili su nosna kongestija, potom sipnja, vrućica >38 °C i hropci. 
Brzi test antigena na RSV učinjen je u 193 dojenčadi i pokazao se pozitivnim u 134 (69,4%) slučaja. U velike većine dojenčadi (74,5%) 
primijenjeni su bronhodilatatori, dok su inhalirajući kortikosteroidi davani u 24,6%, a racemični adrenalin u 14,1% dojenčadi. 
 Dodatna terapija kisikom bila je potrebna u samo 5% slučajeva. Rezultati ovoga istraživanja potvrđuju veću incidenciju bronhiolitisa 
u dječaka, a srednje trajanje bolničkog liječenja bilo je 7,6±3,3 dana. Antibiotska terapija primijenjena je u 85,2% dojenčadi, što 
je znatno više od podataka iz drugih objavljenih istraživanja. Stoga treba uložiti dodatne napore kako bi se smanjila primjena 
 antibiotika.
Ključne riječi: dojenče; bronhiolitis; lijekovi; značajke populacije
